众所周知，多发性骨髓瘤（MM）的原发耐药及复发是临床上的难点问题。前期研究中我们建立了针对微环境中特定细胞成分和细胞外基质的递药系统并收获良好的疗效。由于肿瘤相关成纤维细胞（CAF）与MM耐药、复发及预后密切相关，本研究以CAF和骨髓瘤细胞表面均高表达的血小板来源生长因子受体-β (PDGFR-β)为治疗靶点，以与其具有特异性高亲和力的环肽为靶向功能分子，以美国FDA批准的聚酯类材料构建的纳米粒为递药载体，以经典化疗药物紫杉醇为模型药物，建立可以同时破坏CAF和骨髓瘤细胞的主动靶向纳米递药系统。与当前研究侧重于以骨髓瘤细胞为治疗位点相比，该策略的优势在于可以同时破坏MM的种子骨髓瘤细胞及其生存的土壤CAF，为MM的治疗提供新的研究思路。

It was now well recognized that drug resistance and relapse posed great challenge in the treatment of multiple myeloma (MM). In previous study, we developed drug delivery system aiming at special cell component or extracellular matrix in tumor microenvironment and obtained favorable therapeutic effects. As cancer-associated fibroblasts (CAF) was highly associated with the drug resistance, relapse and prognosis of MM. In the present study, an active targeting drug delivery system targeting both CAF and MM cells for MM treatment was developed, with platelet derived growth factor receptor-β (PDGFR-β) overexpressed in both CAF and MM cells as the therapeutic target, cyclopeptide with special affinity for PDGFR-β as the targeting moiety, nanoparticles based on FDA approved polyester material as the carrier and classical chemotherapeutics paclitaxel as the model drug. As compared with current research mainly targeting MM cells, the superiority of the active targeting drug delivery system was that it could simultaneously destroy the seed MM cells and its soil CAF within MM which could open a new avenue for the development of MM treatment regimen.